{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T02:44:08Z","timestamp":1786157048052,"version":"build-2736575974"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science and Technology Major Project for Noncommunicable Chronic Diseases","award":["2025ZD0544300"],"award-info":[{"award-number":["2025ZD0544300"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470181"],"award-info":[{"award-number":["82470181"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570236"],"award-info":[{"award-number":["82570236"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270196"],"award-info":[{"award-number":["82270196"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Relapsed or refractory extranodal natural killer\/T-cell lymphoma (R\/R NKTCL) remains a highly lethal disease, particularly after failure of PD-1 blockade\u2013based therapy. Preclinical data suggest that inhibition of exportin-1 (XPO1) may enhance antitumor immunity and synergize with PD-1 blockade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter, open-label phase 1b study (TOUCH, Arm C) evaluating selinexor plus tislelizumab in patients with R\/R NKTCL previously treated with L-asparaginase\u2013containing regimens. A standard 3\u2009+\u20093 dose-escalation design was followed by dose expansion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventeen patients were enrolled; 16 had prior checkpoint inhibitor (CPI) exposure and comprised the efficacy population. No dose-limiting toxicities were observed. Grade \u22653 treatment-emergent adverse events occurred in 52.9% of patients; hematologic toxicities were the most common. Among patients with prior CPI exposure, the overall response rate was 75.0% (12\/16), including complete responses in 43.8% (7\/16). Responses were observed in patients with primary CPI-refractory disease. With a median follow-up of 21.7\u2009months, median progression-free survival was 6.1\u2009months (95% CI, 2.9\u2013not estimable), and the 2-year progression-free survival rate was 37.5%. Median overall survival was not reached; the 2-year overall survival rate was 73.4%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Selinexor plus tislelizumab demonstrated manageable toxicity and substantial activity in patients with relapsed\/refractory NKTCL previously treated with CPI, supporting further evaluation of nuclear export inhibition as a strategy to re-engage antitumor immunity after failure of PD-1 blockade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov identifier<\/jats:title>\n                    <jats:p>NCT04425070.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag266","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:51:15Z","timestamp":1783684275000},"source":"Crossref","is-referenced-by-count":0,"title":["Selinexor plus tislelizumab in patients with relapsed\/refractory natural killer\/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial"],"prefix":"10.1093","volume":"31","author":[{"given":"Chuanxu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai, 200032,","place":["China"]},{"name":"Research Center for Lymphoma, Fudan University , Shanghai, 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai, 200032,","place":["China"]},{"name":"Research Center for Lymphoma, Fudan University , Shanghai, 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-Sen University Cancer Center , Guangzhou, 510060,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai, 200032,","place":["China"]},{"name":"Research Center for Lymphoma, Fudan University , Shanghai, 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Guo","sequence":"additional","affiliation":[{"name":"Antengene Therapeutics Ltd , Shanghai, 200051,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Antengene Therapeutics Ltd , Shanghai, 200051,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-Sen University Cancer Center , Guangzhou, 510060,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5766-1625","authenticated-orcid":false,"given":"Rong","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai, 200032,","place":["China"]},{"name":"Research Center for Lymphoma, Fudan University , Shanghai, 200032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"2026080722165030600_oyag266-B1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13045-022-01293-5","article-title":"How we treat NK\/T-cell lymphomas","volume":"15","author":"Tse","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026080722165030600_oyag266-B2","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/annonc\/mdx316","article-title":"Beyond first-line non-anthracycline-based chemotherapy for extranodal NK\/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease","volume":"28","author":"Lim","year":"2017","journal-title":"Ann Oncol"},{"key":"2026080722165030600_oyag266-B3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/hon.2977","article-title":"Long-term outcomes and central nervous system relapse in extranodal natural killer\/T-cell lymphoma","volume":"40","author":"Miyazaki","year":"2022","journal-title":"Hematol Oncol"},{"key":"2026080722165030600_oyag266-B4","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"2026080722165030600_oyag266-B5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2026080722165030600_oyag266-B6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4143\/crt.2023.1042","article-title":"Pembrolizumab for patients with relapsed or refractory extranodal NK\/T-cell lymphoma in Korea","volume":"56","author":"Lee","year":"2024","journal-title":"Cancer Res Treat"},{"key":"2026080722165030600_oyag266-B7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood.2024027109","article-title":"Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed\/refractory NK\/T-cell lymphoma","volume":"146","author":"Kim","year":"2025","journal-title":"Blood"},{"key":"2026080722165030600_oyag266-B8","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: an open-label phase 2 study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"2026080722165030600_oyag266-B9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","article-title":"Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)","volume":"6","author":"Tao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026080722165030600_oyag266-B10","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.22.02367","article-title":"Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer\/T-cell lymphoma (GEMSTONE-201): results from a single-arm, multicenter, phase II study","volume":"41","author":"Huang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026080722165030600_oyag266-B11","doi-asserted-by":"crossref","first-page":"78883","DOI":"10.18632\/oncotarget.12428","article-title":"Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF-kappaB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"key":"2026080722165030600_oyag266-B12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1 - from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026080722165030600_oyag266-B13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/1535-7163.MCT-16-0498","article-title":"The exportin-1 inhibitor selinexor exerts superior antitumor activity when combined with T-cell checkpoint inhibitors","volume":"16","author":"Farren","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2026080722165030600_oyag266-B14","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1128\/JVI.74.13.6068-6076.2000","article-title":"Epstein-Barr virus EB2 protein exports unspliced RNA via a crm-1-independent pathway","volume":"74","author":"Farjot","year":"2000","journal-title":"J Virol"},{"key":"2026080722165030600_oyag266-B15","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1093\/oncolo\/oyad241","article-title":"Selinexor with anti-PD-1 antibody as a potentially effective regimen for patients with natural killer\/T-cell lymphoma failing prior L-asparaginase and PD-1 blockade","volume":"29","author":"Tao","year":"2024","journal-title":"Oncologist"},{"key":"2026080722165030600_oyag266-B16","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"2026080722165030600_oyag266-B17","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1182\/bloodadvances.2022009575","article-title":"Treating relapsed\/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study","volume":"7","author":"Bachy","year":"2023","journal-title":"Blood Adv"},{"key":"2026080722165030600_oyag266-B18","doi-asserted-by":"crossref","first-page":"1088685","DOI":"10.3389\/fimmu.2023.1088685","article-title":"Treatment of extranodal NK\/T-cell lymphoma: from past to future","volume":"14","author":"Yan","year":"2023","journal-title":"Front Immunol"},{"key":"2026080722165030600_oyag266-B19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41392-024-01825-0","article-title":"Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib\/II study","volume":"9","author":"Gao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026080722165030600_oyag266-B20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/cells14060430","article-title":"Selinexor\u2019s immunomodulatory impact in advancing multiple myeloma treatment","volume":"14","author":"Tasbihi","year":"2025","journal-title":"Cells"},{"key":"2026080722165030600_oyag266-B21","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41423-024-01187-1","article-title":"Exportin 1 governs the immunosuppressive functions of myeloid-derived suppressor cells in tumors through ERK1\/2 nuclear export","volume":"21","author":"Daneshmandi","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"2026080722165030600_oyag266-B22","doi-asserted-by":"crossref","first-page":"1002310","DOI":"10.37349\/etat.2025.1002310","article-title":"Modulation of anti-tumour immunity by XPO1 inhibitors","volume":"6","author":"Fisher","year":"2025","journal-title":"Explor Target Antitumor Ther"},{"key":"2026080722165030600_oyag266-B23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41419-020-03303-1","article-title":"Targeting XPO1 enhances innate immune response and inhibits KSHV lytic replication during primary infection by nuclear stabilization of the p62 autophagy adaptor protein","volume":"12","author":"Meng","year":"2021","journal-title":"Cell Death Dis"},{"key":"2026080722165030600_oyag266-B24","doi-asserted-by":"crossref","first-page":"e00866-19","DOI":"10.1128\/mBio.00866-19","article-title":"CRISPR-Cas9 screening of Kaposi\u2019s sarcoma-associated herpesvirus-transformed cells identifies XPO1 as a vulnerable target of cancer cells","volume":"10","author":"Gruffaz","year":"2019","journal-title":"mBio"},{"key":"2026080722165030600_oyag266-B25","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"key":"2026080722165030600_oyag266-B26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080722165030600_oyag266-B27","first-page":"2714","article-title":"Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer\/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study","volume":"110","author":"Zhong","year":"2025","journal-title":"Haematologica"},{"key":"2026080722165030600_oyag266-B28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41379-019-0392-8","article-title":"Immune subtyping of extranodal NK\/T-cell lymphoma: a new biomarker and an immune shift during disease progression","volume":"33","author":"Cho","year":"2020","journal-title":"Mod Pathol"},{"key":"2026080722165030600_oyag266-B29","first-page":"101550","article-title":"Extranodal NK\/T-cell lymphoma: an update of the molecular characterization of the tumor and microenvironment, and its clinical implications","volume":"62","author":"Chan","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"key":"2026080722165030600_oyag266-B30","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00262-017-1987-x","article-title":"Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer\/T-cell lymphoma: a potential rationale for immunotherapy","volume":"66","author":"Nagato","year":"2017","journal-title":"Cancer Immunol Immunother"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag266\/68762760\/oyag266.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag266\/68762760\/oyag266.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag266\/68762760\/oyag266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T02:17:01Z","timestamp":1786155421000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag266\/8733089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag266","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,11]]},"article-number":"oyag266"}}